Physician profile
Katherine E Bouchard
NPI 1750944708
$5,342.24
in general payments reported to CMS, 2019-2025
24 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.00 · 2022: $386 · 2023: $1,751 · 2024: $1,545 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,936.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $813.07 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $720.63 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $609.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $596.10 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $329.15 | 2022-2024 | Spravato, Xarelto |
| Pfizer INC. | $272.04 | 2023-2025 | |
| Astellas Pharma US INC | $264.07 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.99 | 2022-2025 | Xifaxan |
| Amgen INC. | $220.90 | 2022-2024 | Otezla, Repatha |
| Abbott Laboratories | $203.05 | 2024-2025 | Freestyle Libre 3 |
| Viiv Healthcare Company | $156.64 | 2022-2025 | Apretude |
| Glaxosmithkline, LLC. | $150.20 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Idorsia Pharmaceuticals US INC | $139.90 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $103.50 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $100.30 | 2022-2023 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $92.12 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $81.01 | 2025 | |
| Axsome Therapeutics, INC. | $63.43 | 2025 | Auvelity |
| Dexcom, INC. | $50.68 | 2025 | Dexcom G6 Transmitter |
| Tris Pharma INC | $38.85 | 2023 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $24.33 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.92 | 2022 | |
| Dynavax Technologies Corporation | $18.23 | 2023 | Heplisav-B |
| Gt Medical Technologies, INC | $13.87 | 2023 | Gammatile |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Bouchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.